Stay updated on Bispecific Antibody MCLA-158 Clinical Trial
Sign up to get notified when there's something new on the Bispecific Antibody MCLA-158 Clinical Trial page.

Latest updates to the Bispecific Antibody MCLA-158 Clinical Trial page
- Check2 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3. This represents a minor version update with no substantive content updates.SummaryDifference0.0%

- Check10 days agoNo Change Detected
- Check17 days agoNo Change Detected
- Check24 days agoChange DetectedGastric cancer has been added to the Conditions list. The Genetic and Rare Diseases Information Center is now listed as a resource, and the page revision was updated from v3.4.1 to v3.4.2.SummaryDifference0.1%

- Check31 days agoChange DetectedMerus N.V. was removed and Merus B.V. was added as the sponsor. The page revision updated from v3.4.0 to v3.4.1.SummaryDifference0.2%

- Check46 days agoChange DetectedGlossary toggle controls were added (Show glossary, Hide glossary) and new metadata items Last Update Submitted that Met QC Criteria and No FEAR Act Data were introduced, along with a revision note Revision: v3.4.0. The older variants Last Update Submitted that met QC Criteria, No FEAR Act data, and Revision: v3.3.4 were removed.SummaryDifference0.2%

- Check54 days agoChange DetectedRevision tag updated from v3.3.3 to v3.3.4 on the page.SummaryDifference0.0%

- Check82 days agoChange DetectedThe page's Locations section was updated to include a consolidated list of states. Individual state location pages were removed, and the revision updated to v3.3.3.SummaryDifference0.8%

Stay in the know with updates to Bispecific Antibody MCLA-158 Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Bispecific Antibody MCLA-158 Clinical Trial page.